The Nemours Children's Health System, an internationally recognised children's health system that owns and operates the two free-standing hospitals, has named Robert G Riney as its chair, effective immediately, it was reported yesterday.
Riney has served on the Nemours Foundation Board since 2006. He succeeds Brian Anderson who has been a Nemours board member for 13 years, serving as chair for the last three years. He has served as chief operating officer of Henry Ford Health System since 2003. He was appointed president of healthcare operations and chief operating officer in 2017. He manages all hospital and service operations for the six-hospital health system, consisting of more than 60 clinical locations, 30,000 employees and annual revenues of USD6bn.
In addition, Riney is responsible for Corporate Information Technology, Corporate Facilities & Security, International Strategies, and the System Chief Nursing Office. He has served in almost every business unit in the System throughout his career. Active in his community and healthcare nationally, he is vice chair of the National Center for Healthcare Leadership (NCHL), board member and past-chair of the Michigan Health & Hospital Association (MHA), and a board member of the Detroit Zoological Society, M1 Rail Transit Authority, The Parade Company, and the Hudson-Webber Foundation.
Larry Moss, MD, president and CEO of Nemours Children's Health System, said, 'Bob Riney possesses a remarkable combination of vast healthcare expertise and accomplishment in addition to superb leadership abilities. In the short time we have worked together, I have come to respect him immensely, and I look forward with great enthusiasm as Bob and his board colleagues collaborate with Nemours senior leaders and me to create the future of this very special organisation.'
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025